Search Results

You are looking at 141 - 150 of 383 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Daniel Y. C. Heng and Toni K. Choueiri

; 356 : 125 – 134 . 16 Escudier B Koralewski P Pluzanska A . A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma

Full access

Stefan W. Krause, Jan Schildmann, Christian Lotze, and Eva C. Winkler

given examples of treatments withheld on the grounds of unconvincing evidence and based on an unfavorable cost/benefit analysis were erlotinib, bevacizumab, and other antibodies ( Table 3 , Q5 and Q7). Typical examples for withholding treatments because

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar

least 6 weeks, or confirmed partial response or complete response using RECIST was 64%. The median OS was 27 months. 27 Other Therapies for Patients With Non-Clear Cell Carcinomas Bevacizumab is a humanized monoclonal antibody that binds and

Full access

Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna

these agents, novel therapies or combinations are needed. A recent phase II study met its primary endpoint by showing improved progression-free survival with the combination of TAS-102/bevacizumab compared with TAS-102 alone in patients with refractory

Full access

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

as bevacizumab, sorafenib, or sunitinib, could complement the downstream antiangiogenic effect of mTOR inhibition. Various tyrosine kinase inhibitors could interrupt the activation of various upstream mTOR signaling pathways, thus complementing direct

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory

. 118 , 119 Targeted Therapies: Specific targeted therapies have been developed for the treatment of advanced lung cancer. 120 , 121 Bevacizumab is a recombinant monoclonal antibody that blocks the vascular endothelial growth factor (VEGF). Erlotinib

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

, temsirolimus, everolimus, and bevacizumab in combination with interferon. Tumor histology and risk stratification of patients is important in targeted therapy selection. The most widely used model for risk stratification is the MSKCC model, 46 which

Full access

E. Gabriela Chiorean, Marco Del Chiaro, Margaret A. Tempero, Mokenge P. Malafa, Al B. Benson III, Dana B. Cardin, Jared A. Christensen, Vincent Chung, Brian Czito, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Christos Fountzilas, Evan S. Glazer, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Ashiq Masood, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Lorenzo Nardo, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Mark J. Truty, Charles Vollmer Jr, Robert A. Wolff, Brian M. Wolpin, Beth McCullough RN, Senem Lubin, and Susan D. Darlow

intestinal type ampullary cancer, all recommendations are derived from the NCCN Guidelines for Colon Cancer (available at ). Most of the recommendations are based on phase II/III, randomized data (FOLFOXIRI ± bevacizumab, 167 FOLFOX ± bevacizumab

Full access

Aki Morikawa and Andrew D. Seidman

(response rate, 1.45; 95% CI, 1.25–1.68; P <.001). 44 The GeparSixto study evaluated the addition of carboplatin to paclitaxel and pegylated liposomal doxorubicin (plus bevacizumab in TNBC) in the neoadjuvant setting. 45 The addition of carboplatin was

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

believed that they have a broader therapeutic index and are potentially less toxic. 49 Two of these agents, erlotinib and bevacizumab, are currently approved by the FDA for the treatment of NSCLC. Erlotinib, a small molecule epidermal growth factor